312 Folgen
Gastrointestinal Cancer Update Research To Practice
-
- Wissenschaft
This series bridges the gap between research and patient care by providing medical oncologists and hematologists with ongoing access to the perspectives and opinions of national and international clinical investigators with expertise in gastrointestinal cancers.
-
Oncology Today with Dr Neil Love: Role of HER2-Directed Therapy in the Treatment of HER2-Expressing Gastrointestinal Cancers — Part 2 of a Special 3-Part Edition
Dr Kanwal Raghav from The University of Texas MD Anderson Cancer Center in Houston discusses the role of HER2-directed therapy in the treatment of gastrointestinal tumors beyond gastroesophageal cancer.
-
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Colorectal Cancer
Professor Thierry André from the Hôpital Saint-Antoine in Paris, France, and Dr Arvind Dasari from MD Anderson Cancer Center in Houston, Texas, discuss recent developments regarding available and novel treatment strategies for colorectal cancer.
-
Consensus or Controversy? Immune Checkpoint Inhibitors in the Management of Hepatobiliary Cancers — A 2024 Post-ASCO Gastrointestinal Cancers Symposium Review
Dr Robin K (Katie) Kelley from the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California, and Dr Mark Yarchoan from the Johns Hopkins Sidney Kimmel Cancer Center in Baltimore, Maryland, discuss clinical decision-making with numerous treatment strategies for hepatocellular carcinoma and biliary tract cancers.
-
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Gastroesophageal Cancers
Dr Yelena Y Janjigian from Memorial Sloan Kettering Cancer Center in New York and Dr Zev Wainberg from UCLA Jonsson Comprehensive Cancer Center in Los Angeles discuss the management of gastroesophageal cancers and review emerging data sets in the field.
-
Consensus or Controversy? Investigator Perspectives on the Current and Future Role of Immune Checkpoint Inhibitors in the Management of Hepatobiliary Cancers
Dr Ahmed Omar Kaseb from the University of Texas MD Anderson Cancer Center in Houston, Texas, and Prof Arndt Vogel from Schwartz Reisman Liver Research Centre in Toronto, Ontario, discuss the optimal selection and sequencing of checkpoint inhibitor therapy for patients with hepatobiliary cancers.
-
Inside the Issue: Targeted and Immunotherapeutic Approaches for Biliary Tract Cancers
Dr Lipika Goyal from The Stanford Cancer Center and Dr Milind Javle from The University of Texas MD Anderson Cancer Center in Houston discuss targeted and immunotherapeutic approaches for biliary tract cancers.